Navigation Links
Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia
Date:12/11/2009

SAN DIEGO, Dec. 11 /PRNewswire/ -- Ambit Biosciences Corporation announced today the enrollment and dosing at the University of Texas M. D. Anderson Cancer Center of the first patient in the ACE (AC220 Monotherapy Efficacy) Phase 2 pivotal trial in patients with relapsed or refractory acute myeloid leukemia (AML). AC220 is a novel, orally available, potent and highly selective small molecule that was specifically designed as a FMS-like tyrosine kinase-3 (FLT3) inhibitor. The ACE study is designed to be a pivotal trial that could potentially support a United States regulatory filing for AC220 to address a targeted AML patient population with the internal tandem duplication (ITD) activating mutation for FLT3.

"Based on the promising results of our first-in-human clinical trial presented at the American Society of Hematology (ASH), we are pleased to advance AC220 into this important Phase 2 study in AML. We are deeply grateful to our investigators, their staff, and their patients, as well as our entire team at Ambit, for their vital contributions in achieving this significant milestone," said Wendell Wierenga, EVP of Research and Development at Ambit. "If the ACE study is successful, AC220 could emerge as the first once-a-day, orally available targeted therapy for AML patients. Over the next several months we plan to initiate additional clinical trials with AC220 to support the potential registration in AML, and to explore its utility in certain types of solid tumors."

"AML is a devastating disease for which few treatment options exist," said Jorge Cortes MD, Internist and Professor, Deputy Chair, Department of Leukemia, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, and principal investigator for the ACE Study. "There are no treatments currently approved by the FDA that specifically target the activating ITD mutations of the FLT3 kinase, present in 2
'/>"/>

SOURCE Ambit Biosciences Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT
2. YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES
3. Cell Biosciences Acquires Protein Forest
4. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
5. Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops
6. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
7. YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
8. American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
9. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
10. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING
11. Regado Biosciences to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)...  Yongye International, Inc. (NASDAQ: YONG ) ... distributor of crop nutrient products in the ... on May 16, 2013, the special committee (the "Special ... Directors") was provided a letter (the "Letter") issued by ... Limited ("Abax") to Full Alliance International Limited ("Full Alliance"). ...
(Date:5/17/2013)... 2013 The paradigm of ‘one drug, ... that can help predict the adverse and therapeutic effects ... Head of Computational Biology at the Genomics Laboratory, Covance, ... ensure high-quality genomics when used as part of the ... complex data sets to identify key clinical targets even ...
(Date:5/17/2013)... Tooth decay is an epidemic in American children with 50% ... World Health Organization says that worldwide, 60–90% of ... are the long-term effects of this transmissible infection? , ... oral bacterial imbalance and serious systemic issues like heart disease. ... also 100% preventable? Answer: there has been no way to ...
(Date:5/16/2013)... May 16, 2013 In late 2012, Dr. ... speak to doctors in China about Appearance Medicine . ... this was her first trip to lecture in China, and ... Guangzhou and Fuzhou, home to 12 and 7 million people ... very high at this point in time. As Dr. Hart ...
Breaking Biology Technology:Yongye International Provides Update on Status of Proposed Go Private Offer 2Yongye International Provides Update on Status of Proposed Go Private Offer 3Yongye International Provides Update on Status of Proposed Go Private Offer 4Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 2Seeing the Future: How a Revolutionary New Bacterial Screening Device Can Predict a Patient’s Future for Tooth Decay 3
... the size of a dorm refrigerator in one of Himadri B. ... the cool light of red, blue and green LEDS. This ... The soup is colored by a strain of blue-green bacteria ... their nearest competitorsin part because of their unique genetic endowment but ...
... has announced that it has registered with the ... into a commercialization agreement with Kentucky-based Union Springs ... exclusive antimicrobial polymer, HM4100.  The unique and effective ... degrading effects of bacteria, mold, mildew and fungi. ...
... Dec. 14, 2010 Tolerx, Inc., a biopharmaceutical company ... by modulating T cell activity, today announced that it ... the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of TRX518, ... by enabling T cells to more effectively attack cancer ...
Cached Biology Technology:Champion hydrogen-producing microbe 2Champion hydrogen-producing microbe 3Champion hydrogen-producing microbe 4Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals 2Pittsburgh-based BIOSAFE Receives EPA Registration and Enters Into Commercialization Agreement with Union Springs Pharmaceuticals 3Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer 2Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer 3
(Date:5/16/2013)... ancient shorelines to predict the stability of today,s largest ice ... from three million years ago, for example when Earth ... be evidence of a high sea level due to ice ... scientists to think that if the world,s largest ice sheets ... same in our modern, progressively warming world. , However, ...
(Date:5/16/2013)... BOSTON The endothelium, the cellular layer lining ... just a few hundred nanometers in thickness, this ... stretch and tissue compression to create a unique ... necessary to partition tissues from the body,s circulatory ... when the barrier must be physically breached ...
(Date:5/16/2013)... Integrated Biometrics patented LES (Light Emitting ... film transistor camera introduces Sherlock, a fingerprint scanner ... the smallest and lightest form factor available on ... ID FAP 45, Certified scanner is highly efficient ... weight when compared to optical scanners. ...
Breaking Biology News(10 mins):World's biggest ice sheets likely more stable than previously believed 2Endothelium, heal thyself 2Endothelium, heal thyself 3Endothelium, heal thyself 4
... have developed a method for training the common honey ... Based on knowledge of bee biology, the new techniques ... the use of improvised explosive devices, or IEDs, which ... and is an emerging danger for civilians worldwide. ...
... Vertebrate creatures first began moving from the world's oceans to ... by 360 million years ago. The fossil record contains few ... years, and then suddenly vertebrates show up again, this time ... land is known as Romer's Gap, named for the Yale ...
... Texas M. D. Anderson Cancer Center are now able to ... help keep breast cancer cells alive. , In the Sept. ... roles to a number of genes and proteins thought to ... the process, have identified potential molecular drug targets. , "It's ...
Cached Biology News:Detecting explosives with honeybees 2Steep oxygen decline halted first land colonization by Earth's sea creatures 2New path from estrogen to survival in breast cancer cells described 2New path from estrogen to survival in breast cancer cells described 3
GEL FILTRATION CAL KIT HMW, 1 EA. *Category: Gel Filtration Gels....
... provides the premium quality siRNAs you need ... can be readily ordered online by providing ... by providing the sense and antisense siRNA ... Validated and Silencer Pre-designed ...
Human FGF R2 (alpha isoforms) MAb (Clone 98706)...
8.1.1...
Biology Products: